Qiagen N.V.

ots Ad hoc-Service: QIAGEN N.V. QIAGEN AND ZYMARK ANNOUNCE STRATEGIC ALLIANCE TO ADDRESS ULTRA HIGH-THROUGHPUT ENVIRONMENTS

Ad hoc-announcement. The sender is solely responsible for the contents of this announcement. -----------------------------------------------------

    Venlo, The Netherlands and Hopkinton, Massachusetts (ots Ad
hoc-Service) -      
    
    QIAGEN, N.V. (Nasdaq: QGENF, Neuer Markt: QIA, Easdaq: QGEN) and
Zymark Corporation today announced that they have entered into a
strategic alliance addressing the use of ultra high-throughput sample
and liquid handling automation. The alliance will focus on uses of
such instrumentation for nucleic acid handling and purification as
well as for QIAGEN's proprietary protein expression and purification
technology. QIAGEN develops and markets liquid handling platforms
which automate the Company's market and technology leading nucleic
acid handling, separation and purification consumables. Zymark has
created leading solutions for the integration of such systems into
fully integrated solutions for ultra high- throughput applications.
The companies intend to develop and launch systems which will combine
QIAGEN's BioRobot automated instrumentation platforms with Zymark's
RapidPlate 96-well and 384-well pipetting solutions and Zymark's
Staccato and Twister systems to address the rapidly expanding need
for ultra high-throughput nucleic acid handling, separation and
purification solutions in the genomics markets. Under the terms of
the agreement, Zymark will supply its ultra high-throughput
automation technologies to QIAGEN, and QIAGEN will market to its
customers the Zymark technologies in combination with QIAGEN's broad
portfolio of market and technology-leading nucleic acid purification
consumable and instrumentation technologies via QIAGEN's extensive
marketing organization. QIAGEN and Zymark also intend to enter into
research and development programs to expand the uses of the
combination of each company's instrumentation components with QIAGEN'
nucleic acid handling, separation and purification consumable
technologies.

    QIAGEN N.V. Peer M. Schatz Chief Financial Officer +49 (0)2103 29-11702 e-mail: p.schatz@de.QIAGEN.com

    WKN: 901626; Index: NEMAX50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Hannover und Stuttgart

End ----------------------------------------------------- Internet: http://recherche.newsaktuell.de



Das könnte Sie auch interessieren: